Direkt zum Inhalt
Merck

Immune effector mechanisms implicated in atherosclerosis: from mice to humans.

Immunity (2013-07-03)
Peter Libby, Andrew H Lichtman, Göran K Hansson
ZUSAMMENFASSUNG

According to the traditional view, atherosclerosis results from a passive buildup of cholesterol in the artery wall. Yet, burgeoning evidence implicates inflammation and immune effector mechanisms in the pathogenesis of this disease. Both innate and adaptive immunity operate during atherogenesis and link many traditional risk factors to altered arterial functions. Inflammatory pathways have become targets in the quest for novel preventive and therapeutic strategies against cardiovascular disease, a growing contributor to morbidity and mortality worldwide. Here we review current experimental and clinical knowledge of the pathogenesis of atherosclerosis through an immunological lens and how host defense mechanisms essential for survival of the species actually contribute to this chronic disease but also present new opportunities for its mitigation.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Cholesterin, Sigma Grade, ≥99%
Sigma-Aldrich
Cholesterin, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
Cholesterin, from sheep wool, ≥92.5% (GC), powder
Sigma-Aldrich
SyntheChol® NS0-Supplement, 500 ×, synthetic cholesterol, animal component-free, aqueous solution, sterile-filtered, suitable for cell culture
Supelco
Cholesterin -Lösung, certified reference material, 10 mg/mL in chloroform
SAFC
Pflanzliches Cholesterin, SyntheChol®
Sigma-Aldrich
Cholesterin, from lanolin, ≥99.0% (GC)
Sigma-Aldrich
Cholesterin, tested according to Ph. Eur.